---
title: Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell
  proteome
date: '2024-03-23'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38521003/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240324180521&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Precision oncology has revolutionized the treatment of ALK-positive lung
  cancer with targeted therapies. However, an unmet clinical need still to address
  is the treatment of refractory tumors that contain drug-induced resistant mutations
  in the driver oncogene or exhibit resistance through the activation of diverse mechanisms.
  In this study, we established mouse tumor-derived cell models representing the two
  most prevalent EML4-ALK variants in human lung adenocarcinomas and characterized
  ...
disable_comments: true
---
Precision oncology has revolutionized the treatment of ALK-positive lung cancer with targeted therapies. However, an unmet clinical need still to address is the treatment of refractory tumors that contain drug-induced resistant mutations in the driver oncogene or exhibit resistance through the activation of diverse mechanisms. In this study, we established mouse tumor-derived cell models representing the two most prevalent EML4-ALK variants in human lung adenocarcinomas and characterized ...